Furthermore, tumours that over-express the Myc protein should be amenable to therapeutic modalities such as anti-sense and siRNA that specifically target c-Myc resulting in efficacious management of oral cancers. This evidence concerns the gene MYC and lip and oral cavity carcinoma.